Iezhitsa I N, Spasov A A, Bugaeva L I
Medical Academy, Research Institute of Pharmacology, 1 Pavshikh Bortsov sq., Volgograd 400066, Russia. pharm@avtlg@ru
Neurotoxicol Teratol. 2001 Mar-Apr;23(2):213-22. doi: 10.1016/s0892-0362(01)00119-2.
Bromantan (N-[2-adamantil]-N-[para-bromphenyl]amine) is an "actoprotective" drug widely used in Russia as a muscle performance-enhancing agent for sportsmen and as an immunostimulator in medicine. Experiments were conducted to determine whether this compound has adverse effects on the reproduction and development of offspring. Sexually mature female rats, weighing 180-200 g, were orally given bromantan at doses of 30 mg/kg (30-mg/kg group), 150 mg/kg (150-mg/kg group) and 600 mg/kg (600-mg/kg group) daily for 16 days, while the controls received the vehicle, amylaceous solution. Afterwards, treated females were mated with untreated males. The body weight change of the pregnant rats was monitored, as well as the length of gestation, litter size, sex ratio and number of stillborn. The offsprings were weighed and observed for external malformations, abnormalities of conditioned and unconditioned reflexes and open-field behaviour. Observation of rat dams revealed that their general state and activity in all groups did not differ significantly both during and after bromantan treatment. Bromantan had no adverse effects on body weight and gestation length of dams. Number of dams delivered per group did not differ from controls. There were stillborn rat pups in all litters, but the control group had less. One dam in the first group delivered a rat pup with a head hematoma. Litter size of the 30- and 600-mg/kg groups was decreased (by 34.9% and 44.2%, respectively) and increased in the 150-mg/kg group (by 45.1%, P< .05) in comparison with controls. Bromantan had insignificant different effects on the sex ratio of newborn in all treatment groups. Survival of pups over the first 3 months showed a loss of 40% for the 150-mg/kg group and 20% for controls. During the remaining time, death rate did not exceed 3-6% and did not differ from those of the controls. Pups in the 30- and 600-mg/kg groups showed significantly higher weight gain during the first week (7th PND) of observation by 83.69% and 58.02%, respectively, compared to controls; subsequently, this difference in the 600-mg/kg group decreased rapidly to insignificant levels, but the 30-mg/kg group remained significantly different until PND 35 and then again at PND 77-112. Dynamics of body weight gain of rat pups in the 150-mg/kg group during the whole (but not on PND 7) period of observation was insignificantly (on PNDs 14, 42 and 49 significantly) lower than that of the control group. Study of the functional state of rat pups' nervous system at different stages of postnatal development revealed insignificant differences in the expression of reflexes compared with those of the control group. Negative geotaxis was completed by the 8th day in controls and in treated groups earlier by an average of 1-2 days. Surface righting was completed by the controls on the 8th day, in the 30-mg/kg group on the 6th day and in other treated groups on the 7th day. Cliff avoidance appeared a day ahead for rat pups in treated groups compared with controls. Air righting reflex in the 30- and 600-mg/kg groups was observed a day earlier than in the controls. Significant differences were observed only for two parameters (negative geotaxis and surface righting); in both cases, rat pups of the 30-mg/kg group differed from the control and 150-mg/kg groups. Early development of physical parameters was also noted, but significant differences from the control group were obtained only in the 30-mg/kg group for incisor eruption. While all pups demonstrated strength of fore and hind limbs by postnatal day 16, treated pups increased their times of maintaining their grasp (PND 15). Open-field testing (PND 40) resulted in an insignificant decrease of exploratory and locomotor behaviors for the 30-, 150- and 600-mg/kg groups. The number of grooming episodes was insignificantly decreased for the 30-mg/kg group and insignificantly increased for the 600-mg/kg group. In the passive avoidance testing, on the retention day (72 h later), entry latency for rat pups in the 30-, 150- and 600-mg/kg groups increased by 259.0%, 175.3% and 160.7%, respectively (P< .05), over their training day, while in the control group, time increased only by 1.8%.
溴美他尼(N-[2-金刚烷基]-N-[对溴苯基]胺)是一种“抗疲劳”药物,在俄罗斯被广泛用作运动员增强肌肉性能的药物,以及医学上的免疫刺激剂。进行实验以确定该化合物是否对后代的繁殖和发育有不良影响。选用体重180 - 200 g的性成熟雌性大鼠,每天经口给予溴美他尼,剂量分别为30 mg/kg(30 - mg/kg组)、150 mg/kg(150 - mg/kg组)和600 mg/kg(600 - mg/kg组),持续16天,而对照组给予赋形剂淀粉溶液。之后,将处理过的雌性大鼠与未处理的雄性大鼠交配。监测孕鼠的体重变化、妊娠期长度、窝仔数、性别比例和死产数。对后代进行称重,并观察其外部畸形、条件反射和非条件反射异常以及旷场行为。对母鼠的观察表明,在溴美他尼治疗期间及之后,所有组的母鼠的一般状态和活动均无显著差异。溴美他尼对母鼠的体重和妊娠期长度没有不良影响。每组分娩的母鼠数量与对照组无差异。所有窝均有死产幼鼠,但对照组的死产数较少。第一组中有一只母鼠产下一只头部有血肿的幼鼠。与对照组相比,30 - mg/kg组和600 - mg/kg组的窝仔数减少(分别减少34.9%和44.2%),而150 - mg/kg组增加(增加45.1%,P <.05)。溴美他尼对所有治疗组新生鼠的性别比例影响不显著。150 - mg/kg组幼鼠在出生后的前3个月存活率为40%,对照组为20%。在剩余时间里,死亡率不超过3 - 6%,与对照组无差异。在观察的第一周(出生后第7天),30 - mg/kg组和600 - mg/kg组幼鼠的体重增加分别比对照组显著高83.69%和58.02%;随后,600 - mg/kg组的这种差异迅速降至不显著水平,但30 - mg/kg组直到出生后第35天以及之后的出生后第77 - 112天仍与对照组有显著差异。150 - mg/kg组幼鼠在整个观察期(除出生后第7天外)的体重增加动态与对照组相比无显著差异(在出生后第14、42和49天有显著差异)。对幼鼠神经系统在出生后不同发育阶段功能状态的研究表明,与对照组相比,反射表达的差异不显著。对照组在第8天完成负趋地性,处理组平均提前1 - 2天完成。对照组在第8天完成表面翻正,30 - mg/kg组在第6天完成,其他处理组在第7天完成。与对照组相比,处理组幼鼠的避崖反应提前一天出现。30 - mg/kg组和600 - mg/kg组的空中翻正反射比对照组提前一天观察到。仅在两个参数(负趋地性和表面翻正)上观察到显著差异;在这两种情况下,30 - mg/kg组的幼鼠与对照组和150 - mg/kg组不同。还注意到身体参数的早期发育,但仅在30 - mg/kg组的门齿萌出方面与对照组有显著差异。虽然所有幼鼠在出生后第16天均表现出前肢和后肢的力量,但处理组幼鼠保持抓握的时间增加(出生后第15天)。旷场试验(出生后第40天)结果显示,30 - mg/kg组、150 - mg/kg组和600 - mg/kg组的探索和运动行为略有减少。30 - mg/kg组的理毛次数略有减少,600 - mg/kg组略有增加。在被动回避试验中,在保留日(72小时后),30 - mg/kg组、150 - mg/kg组和600 - mg/kg组幼鼠的进入潜伏期分别比训练日增加了259.0%、175.3%和160.7%(P <.05),而对照组仅增加了1.8%。